RAD Official Website
Menu
Home
More About RAD
Images

Disclaimer
The files, software, and interface on this site are for academic use only. They are not intended for clinical practice in any way, shape, or form. The creators of all content assume no liability for negligent or improper use. Furthermore, all content is © Allen Holder and associated researchers.

 

Radiotherapy optimAl Design (RAD) is a research oriented treatment design system whose modular construction harnesses the power of tailored software to record, model, and solve the underlying optimization problem. This modular design facilitates experimentation with different optimization models, including different objective functions, and different solvers for each model. Moreover, RAD was designed from its inception to consider simultaneous optimization of both beam selection and fluence optimization, and adding concerns about delivery, such as efficient collimator sequencing, is planned. One of the overriding goals is to see how different optimization models and solution techniques fare in an environment that simultaneously attempts to optimize the entirety of treatment design. Other research goals are to investigate:

  • Dose Point Placement
  • Isocenter determination
  • Multiple Targets with non-uniform fractionation
  • Hotspot Prediction
  • Visualization
  • Problem Library Development

We are thankful for the support of several organizations,

  • Summer 2006, Allen Holder (Trinity University), Paul Uhlig (St. Mary's University), Arthur Hanna (St. Mary's University), and Bill Salter (Huntsman Cancer Institute). Supported by The Department of Medical Physics, Huntsman Cancer Institute.
  • Summer 2005, Allen Holder (Trinity University), Ryan Acosta (Trinity University), Josh Reese (Trinity University), William Brick (Trinity University), Domingo Lara (Trinity University) and Bill Salter (Cancer Therapy Research Center). Supported by the Cancer Therapy Research Center and an associated NSF-SURF grant.
  • Summer 2004, Allen Holder (Trinity University), Ryan Acosta (Trinity University), Daniel Nevin (Trinity University), and Bill Salter (Cancer Thereapy Research Center). Supported by the Cancer Therapy Research Center and an associated NSF-SURF grant.